Methyl iodide → 1-[1-(4-Chlorophenyl)-5-isopropyl-pyrazol-4-yl]-3-methyl-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one
Reaction equation
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([N:8]2[C:12]([CH:13]([CH3:15])[CH3:14])=[C:11]([N:16]3[CH2:20][CH2:19][CH:18]([N:21]4[CH:25]=[C:24]([C:26]([F:29])([F:28])[F:27])[N:23]=[C:22]4[CH3:30])[C:17]3=[O:31])[CH:10]=[N:9]2)=[CH:4][CH:3]=1.[H-].[Na+].CI.[NH4+].[Cl-].[C:38](O)(C(F)(F)F)=O>CN(C=O)C>[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([N:8]2[C:12]([CH:13]([CH3:14])[CH3:15])=[C:11]([N:16]3[CH2:20][CH2:19][C:18]([CH3:38])([N:21]4[CH:25]=[C:24]([C:26]([F:28])([F:27])[F:29])[N:23]=[C:22]4[CH3:30])[C:17]3=[O:31])[CH:10]=[N:9]2)=[CH:6][CH:7]=1Participants
Reactant 5
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of 1-[1-(4-chlorophenyl)-5-isopropylpyrazol-4-yl]-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one (50 mg, 0.11 mmol) was added DMF (2 mL) and NaH (60% in mineral oil, 16 mg, 0.33 mmol) slowly at room temperature under nitrogen atmosphere. After stirring for 10 min at room temperature, MeI (34 μL, 0.55 mmol) was added and further stirred for 2 h. Saturated NH4Cl solution (10 mL) was then added at 0° C. slowly to the reaction mixture followed by extraction with EtOAc (2×25 mL). The combined EtOAc layers were dried (MgSO4), concentrated in vacuo, and purified by reverse phase HPLC (C18 column, acetonitrile-H2O with 0.1% TFA as eluent) to give 1-[1-(4-chlorophenyl)-5-isopropyl-pyrazol-4-yl]-3-methyl-3-[2-methyl-4-(trifluoromethyl)imidazol-1-yl]pyrrolidin-2-one (17 mg, 0.029 mmol, 27% yield) as a TFA salt. 1H NMR (400 MHz, Methanol-d4) δ 7.88 (s, 1H), 7.70 (s, 1H), 7.59 (d, J=11.76 Hz, 2H), 7.42 (d, J=11.76 Hz, 2H), 3.86-3.95 (m, 2H), 2.99-3.08 (m, 1H), 2.58-2.80 (m, 2H), 2.52 (s, 3H), 1.96 (s, 3H), 1.22 (d, J=23.4 Hz, 3H), 1.20 (d, J=23.4 Hz, 3H); MS: (ES) m/z calculated for C22H23ClF3N5O [M+H]+466.9. found 466.1.
Workup
- stirringfurther stirred for 2 h
- extractionfollowed by extraction with EtOAc (2×25 mL)
- dry with materialThe combined EtOAc layers were dried (MgSO4)
- concentrationconcentrated in vacuo
- custompurified by reverse phase HPLC (C18 column, acetonitrile-H2O with 0.1% TFA as eluent)
Sources & evidence
- ORD record
- ord-53ffc3a9417d4d36a340a50292a43097
- Source dataset
- uspto-grants-2016_05
- Patent number
- US09328116B2
Reaction notes
Loading…